Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11305761 | 1.00 | DNM1 (0.62) | DNM1MEN1KMT2ATP53MAPK1 | |
| SCHEMBL10034064 | 1.00 | DNM1 (0.62) | DNM1MEN1KMT2ATP53MAPK1 | |
| Miramistin Ion SCHEMBL2236560 | 0.99 | MEN1 (0.63) | DNM1MEN1KMT2ATP53MAPK1 | |
| Hydrochloric Acid SCHEMBL5481757 | 0.99 | MEN1 (0.63) | DNM1MEN1KMT2ATP53MAPK1 | |
| Hydrochloric Acid SCHEMBL5164193 | 0.99 | MEN1 (0.63) | DNM1MEN1KMT2ATP53MAPK1 | |
| Miramistin Ion SCHEMBL23922700 | 0.99 | MEN1 (0.62) | DNM1MEN1KMT2ATP53MAPK1 | |
| Miramistin Ion SCHEMBL17530472 | 0.97 | MEN1 (0.64) | DNM1MEN1KMT2ATP53MAPK1 | |
| SCHEMBL7091153 | 0.94 | EPHX2 (0.62) | DNM1MEN1KMT2ATP53MAPK1 | |
| SCHEMBL7089077 | 0.94 | EPHX2 (0.62) | DNM1MEN1KMT2ATP53MAPK1 | |
| SCHEMBL10108787 | 0.93 | EPHX2 (0.67) | DNM1MEN1KMT2ATP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2990034-A1 | ANTISEPTIC VETERINARY FORMULATION AND METHODS FOR USE THEREOF | Obshchestvo S Ogranichennoy Otvetstvennostyu "Nanobiotekh" (RU) | 2016-03-02 | — | — | EP | claimed |
| EP-2536400-B1 | MEDICAMENT COMPRISING MYRAMISTIN | MEGAINPHARM GMBH (AT) | 2014-09-24 | — | — | EP | claimed |
| CN-116390908-A | Antiviral treatment | 生态合成股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230118459-A1 | ANTIVIRAL TREATMENT | ECOSYNTH NV (BE) | 2023-04-20 | — | — | US | disclosed |
| EP-4114376-A1 | ANTIVIRAL TREATMENT | Ecosynth (BE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022072394-A1 | CURABLE COATING COMPOSITIONS AND ANTIMICROBIAL/ANTIVIRAL COATINGS MADE BY CURING SUCH COATING COMPOSITIONS | GREEN THEME TECHNOLOGIES, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| WO-2021176010-A1 | ANTIVIRAL TREATMENT | ECOSYNTH NV (BE) | 2021-09-10 | — | — | WO | disclosed |
| WO-2014175757-A1 | ANTISEPTIC VETERINARY FORMULATION AND METHODS FOR USE THEREOF | Общество с ограниченной ответственностью "Нанобиотех" (RU) | 2014-10-30 | — | — | WO | disclosed |
| EP-2536400-A1 | PHARMACEUTICAL COMPRISING MYRAMISTIN | Megainpharm GmbH (AT) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101113-A1 | PHARMACEUTICAL COMPRISING MYRAMISTIN | MEGAINPHARM GMBH (AT) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011100994-A1 | PHARMACEUTICAL COMPRISING MYRAMISTIN | MEGAINPHARM GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| WO-1993000892-A1 | PHARMACEUTICAL PREPARATION | KRIVOSHEIN JURY SEMENOVICH (UA) | 1993-01-21 | — | — | WO | disclosed |
| EP-0358572-A1 | Method for affording lasting biocidal properties to a cleaning and/or wiping product based on cellulose | FINANCIERE ELYSEES BALZAC (FR) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118459-A1 | ANTIVIRAL TREATMENT | MAVS, ACE, ACE2 | DNM1 360/4885MEN1 407/4885KMT2A 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.